EGFR and non-small cell lung carcinoma: Notably, increasing evidences have demonstrated that glycolysis is elevated in EGFR-mutated NSCLC cells with acquired EGFR-TKI resistance [8], and targeting glycolytic enzymes has been shown to improve therapeutic response to EGFR TKI in NSCLC [9, 31, 32].